Skip to main content
Premium Trial:

Request an Annual Quote

RXi, UMMS Receive Massachusetts Life Sciences Center Funding for ALS Work

Premium

RXi Pharmaceuticals said this week that its planned collaboration with the University of Massachusetts Medical School to develop an RNAi-based treatment for amyotrophic lateral sclerosis has been selected for matching funding from the Massachusetts Life Sciences Center.

The funding is worth $250,000 per year for two years and will be matched dollar for dollar by RXi. The award is still subject to a formal agreement between RXi and UMMS.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.